{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:18:37Z","timestamp":1781587117833,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jad.2022.10.020","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T03:19:32Z","timestamp":1666235972000},"page":"153-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability"],"prefix":"10.1016","volume":"321","author":[{"given":"Manish K.","family":"Jha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazal","family":"Magharehabed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Turkoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella J.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhukar H.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2022.10.020_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders, fifth rdition (DSM-5\u00ae)","year":"2013"},{"key":"10.1016\/j.jad.2022.10.020_bb0010","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1176\/appi.ajp.2016.16070839","article-title":"Irritability in youths: a translational model","volume":"174","author":"Brotman","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2022.10.020_bb0015","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1755-5949.2009.00102.x","article-title":"RESEARCH: validation of the Massachusetts General Hospital antidepressant treatment history questionnaire (ATRQ)","volume":"16","author":"Chandler","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jad.2022.10.020_bb0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jad.2020.03.106","article-title":"Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"271","author":"Citrome","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2022.10.020_bb0025","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881115581093","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines","volume":"29","author":"Cleare","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2022.10.020_bb0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamapsychiatry.2019.3686","article-title":"New frontiers in irritability research\u2014from cradle to grave and bench to bedside","volume":"77","author":"Eshel","year":"2020","journal-title":"JAMA Psychiatry."},{"key":"10.1016\/j.jad.2022.10.020_bb0035","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/mp.2009.20","article-title":"The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication","volume":"15","author":"Fava","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2022.10.020_bb0040","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2022.10.020_bb0045","article-title":"Recognizing inadequate response in patients with major depressive disorder","volume":"81(3):OT19037BR2","author":"Jackson","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2022.10.020_bb0050","series-title":"SPRAVATO\u2122 (esketamine) nasal spray, CIII, 2020","author":"Janssen Pharmaceuticals","year":"2020"},{"key":"10.1016\/j.jad.2022.10.020_bb0055","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41386-021-01166-4","article-title":"Identifying novel mechanisms and treatment targets for irritability and aggression in psychiatric disorders","volume":"47","author":"Jha","year":"2022","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2022.10.020_bb0060","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1176\/appi.ajp.2018.18030355","article-title":"Irritability and its clinical utility in major depressive disorder: prediction of individual-level acute-phase outcomes using early changes in irritability and depression severity","volume":"176","author":"Jha","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2022.10.020_bb0065","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41386-020-0769-x","article-title":"Association between irritability and suicidal ideation in three clinical trials of adults with major depressive disorder","volume":"45","author":"Jha","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2022.10.020_bb0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/da.23095","article-title":"Association of anger attacks with suicidal ideation in adults with major depressive disorder: findings from the EMBARC study","volume":"38","author":"Jha","year":"2021","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2022.10.020_bb0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jad.2021.04.019","article-title":"Irritability as an independent predictor of concurrent and future suicidal ideation in adults with stimulant use disorder: findings from the STRIDE study","volume":"292","author":"Jha","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2022.10.020_bb0080","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/jamapsychiatry.2013.1957","article-title":"Overt irritability\/anger in unipolar major depressive episodes: past and current characteristics and implications for long-term course","volume":"70","author":"Judd","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2022.10.020_bb0085","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bdi.12941","article-title":"The effectiveness of ketamine on anxiety, irritability, and agitation: implications for treating mixed features in adults with major depressive or bipolar disorder","volume":"22","author":"McIntyre","year":"2020","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2022.10.020_bb0090","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00213-018-4828-5","article-title":"Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study","volume":"235","author":"Morrison","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2022.10.020_bb0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4088\/JCP.v66n0202","article-title":"Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study.","volume":"66","author":"Perlis","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2022.10.020_bb0100","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1600-0447.2008.01298.x","article-title":"Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder","volume":"119","author":"Perlis","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2022.10.020_bb0105","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2022.10.020_bb0110","first-page":"22","article-title":"The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2022.10.020_bb0115","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jad.2022.10.020_bb0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S0033291703001107","volume":"34","author":"Trivedi","year":"2004","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2022.10.020_bb0125","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81(3):19m12891","author":"Wajs","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2022.10.020_bb0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","article-title":"Development and reliability of a structured interview guide for the Montgomery asberg depression rating scale (SIGMA)","volume":"192","author":"Williams","year":"2008","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032722012113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032722012113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T03:32:34Z","timestamp":1759030354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032722012113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":26,"alternative-id":["S0165032722012113"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2022.10.020","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2022.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Janssen Scientific Affairs, LLC. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}